Vyleesi Pharmacogenomics & Genetic Variability: What Your Genes Tell Us About Bremelanotide

What Bremelanotide Is and Why Genetics Matter Here

Bremelanotide works through a neurobiological pathway, not a hormonal one. That distinction matters when you start thinking about why two women with identical HSDD diagnoses can have very different responses to the same 1.75 mg dose. One woman may notice a meaningful shift in desire with minimal side effects. Another may experience significant nausea and no benefit. Genetics is a real, if under-studied, part of that difference.

The drug is a cyclic heptapeptide melanocortin receptor agonist. It binds with high affinity to MC4R and moderate affinity to MC1R, MC3R, and MC5R across central and peripheral tissues. Because the drug acts on a receptor family that is heavily shaped by genetic variation, inherited differences in receptor structure, receptor density, and downstream signaling can alter both its therapeutic effects and its side-effect profile. Dedicated pharmacogenomic trials specific to bremelanotide in women have not yet been published. What follows synthesizes data from the RECONNECT trials, melanocortin receptor genetics literature, and general peptide pharmacokinetic research to build the clearest picture currently possible.

The Approved Indication Is Narrow on Purpose

Bremelanotide received FDA approval in June 2019 specifically for premenopausal women with acquired, generalized HSDD. The premenopausal restriction is not arbitrary. The RECONNECT phase 3 trials enrolled only premenopausal women, meaning there is no efficacy or safety evidence base in postmenopausal women. Extrapolating the drug to women in perimenopause or post-menopause is not supported by trial data.

Why HSDD Is a Female-Specific Diagnosis Worth Taking Seriously

Hypoactive sexual desire disorder affects an estimated 8 to 12 percent of premenopausal women in the United States when defined by the strict DSM-5 criteria of persistent low desire combined with personal distress. The distress criterion matters. Low desire without distress is not HSDD.

How Bremelanotide Works: The Melanocortin Mechanism

Bremelanotide's mechanism sits entirely within the central nervous system's desire circuitry, which separates it from every other female sexual dysfunction treatment on the market.

MC4R Activation in the Hypothalamus

The hypothalamus contains a dense population of MC4R-expressing neurons in the paraventricular nucleus and medial preoptic area. These neurons are part of the pro-sexual descending pathway. When bremelanotide binds MC4R in these regions, it increases dopaminergic and oxytocin-related signaling and simultaneously reduces endogenous opioid inhibition of sexual appetite. The net result, in women who respond, is a shift in the motivational salience of sexual stimuli.

Animal studies in female rodents established this MC4R-mediated pro-sexual effect before human trials began, and the effect was reproduced across species including non-human primates, supporting MC4R as the therapeutic target.

MC1R and the Flushing Connection

MC1R is expressed heavily in vascular endothelium and in melanocytes. Bremelanotide's binding to MC1R is responsible for two of its most common side effects: transient facial flushing and transient hyperpigmentation with repeated use. Approximately 40 percent of women in RECONNECT experienced flushing, most often within the first hour after injection.

MC1R is among the most polymorphic genes in the human genome. Loss-of-function variants, particularly the R151C, R160W, and D294H alleles common in fair-skinned individuals of Northern European ancestry, are associated with reduced receptor signaling efficiency. Whether these variants attenuate the flushing side effect or paradoxically worsen it through compensatory upregulation has not been tested in bremelanotide-specific studies. This is a genuine knowledge gap.

Nausea: A Central and Peripheral Story

Nausea is the side effect most likely to lead women to discontinue bremelanotide. In the RECONNECT trials, 40.4 percent of bremelanotide-treated women reported nausea versus 1.3 percent in the placebo arm. The mechanism involves area postrema MC4R activation, a region of the brainstem that sits outside the blood-brain barrier and functions as a chemoreceptor trigger zone.

Genetic variation in MC4R expression levels in area postrema neurons may explain why some women experience incapacitating nausea at 1.75 mg while others have none. The 1.75 mg dose is the only approved dose in the US, meaning there is currently no clinician-supported lower starting dose option, unlike some European peptide protocols. Pre-dosing with 4 mg oral ondansetron 60 minutes before bremelanotide is an off-label strategy some clinicians use.

Pharmacokinetics and Where Genetics Intervene

Bremelanotide is a synthetic cyclic peptide. Its metabolic fate is unusual compared with small-molecule drugs, and that unusual fate is why standard CYP pharmacogenomics tools are largely irrelevant here.

Peptide Hydrolysis, Not CYP Enzymes

Bremelanotide is metabolized primarily by nonspecific peptide hydrolysis. Proteolytic enzymes in plasma, tissue, and the gut wall cleave the peptide bonds sequentially. CYP2D6, CYP3A4, CYP2C9, and other cytochrome P450 enzymes are not meaningfully involved. This means common pharmacogenomic panels that test for CYP variants (poor metabolizer status, ultrarapid metabolizer status) do not predict bremelanotide exposure or clearance in a clinically useful way.

What Does Affect Drug Exposure

The pharmacokinetic factors that do matter genetically include:

• Protease expression variability: Plasma aminopeptidases, dipeptidyl peptidase activity (DPP-4 notably), and tissue-based serine proteases vary by genotype. Women with naturally lower DPP-4 activity, a phenotype also associated with better response to DPP-4 inhibitor diabetes drugs, may have slower bremelanotide clearance and longer drug exposure windows.
• Body composition and subcutaneous tissue: Subcutaneous injection pharmacokinetics are influenced by subcutaneous adipose depth and regional blood flow. Women with higher visceral adiposity and lower subcutaneous perfusion may have slower and more variable absorption.
• Renal function: The bremelanotide label reports a 1.5-fold increase in AUC in women with severe renal impairment (eGFR <30 mL/min/1.73 m²), making this the one clinically actionable pharmacokinetic modifier currently in the prescribing information.

Subcutaneous Absorption Across the Menstrual Cycle

This is a clinically under-recognized point. Subcutaneous blood flow varies across the menstrual cycle due to cyclic changes in estradiol and progesterone. Estradiol is vasodilatory and may accelerate absorption from subcutaneous depots in the follicular phase. Progesterone's vasoconstrictive effects in the luteal phase may slow absorption. No pharmacokinetic study has formally tested bremelanotide Tmax or Cmax across menstrual cycle phases, leaving this as an open question with real clinical implications for the drug's onset timing.

Genetic Variants That May Predict Response

No clinical pharmacogenomic test currently exists that was built and validated specifically for bremelanotide response prediction. The framework below synthesizes existing melanocortin receptor genetics with the drug's known mechanism to identify the variant categories most likely to matter, and it represents a synthesis not found in published bremelanotide review articles.

MC4R Variants and Efficacy Prediction

MC4R is one of the most medically significant G-protein-coupled receptors in human biology. Over 150 loss-of-function MC4R variants have been identified, and heterozygous loss-of-function is the most common single-gene cause of obesity in adults, affecting roughly 1 in 1,000 to 1 in 2,000 people. Women who carry heterozygous MC4R loss-of-function variants may have reduced receptor density or signaling efficiency in the hypothalamic pro-sexual pathway. The theoretical prediction is attenuated therapeutic response, but this has not been tested in an HSDD population.

Conversely, MC4R gain-of-function variants are rare but do exist. A woman carrying a sensitizing MC4R variant might theoretically be at higher risk for dose-related adverse effects at the standard 1.75 mg dose.

MC1R Polymorphisms and Side-Effect Susceptibility

Because MC1R governs both pigmentation and vascular response, the many common MC1R variants that determine hair color and skin type are also candidate predictors of bremelanotide flushing severity. Women with two loss-of-function MC1R alleles (the "red hair color" genotype, present in roughly 1 to 2 percent of the global population) may experience different flushing intensity than women with fully functional receptors, though the directionality is uncertain.

POMC, AgRP, and the Wider Melanocortin System

Bremelanotide mimics alpha-melanocyte-stimulating hormone (alpha-MSH), which is derived from the proopiomelanocortin (POMC) gene. Genetic variants in POMC that reduce normal alpha-MSH tone could, theoretically, make a woman's system more or less sensitive to an exogenous MC4R agonist. POMC haploinsufficiency is a rare cause of severe obesity and disrupted reproductive signaling in women, and women with this variant would likely have disrupted baseline melanocortin tone that could alter drug response in unpredictable ways.

Agouti-related peptide (AgRP) is the endogenous MC4R antagonist. AgRP tone modulates how much effect an agonist like bremelanotide can produce. Genetic variants affecting AgRP expression or stability are poorly characterized but represent a theoretical source of between-patient variability.

Who This Drug Is Right For, and Who It Is Not

Life stage and comorbidity dramatically narrow the right-candidate population. Being clear about this protects women from inappropriate prescribing.

Reproductive Years: The Approved Window

Bremelanotide is approved and studied only in premenopausal women. The best candidate is a woman in her reproductive years (typically ages 18 to 50) who has:

• A documented change from her own prior level of desire (acquired HSDD, not lifelong)
• Distress about the change
• No untreated contributing medical cause (hypothyroidism, depression, relationship distress, inadequate stimulation)
• No uncontrolled hypertension

A woman with PCOS and HSDD is a plausible candidate if her HSDD persists after optimizing androgen and metabolic management, since PCOS-related androgen excess does not necessarily protect against HSDD and can coexist with it.

Perimenopause: A Gray Zone

Women in perimenopause represent a gray zone. The ovaries are still producing estrogen cyclically, but progesterone and testosterone are declining. Perimenopausal women were not included in RECONNECT. A 47-year-old woman still having periods but experiencing vasomotor symptoms sits outside the studied population. Some clinicians prescribe off-label in this group, but the evidence base does not exist to support a recommendation.

Post-Menopause: Not Supported by Evidence

Postmenopausal women have a different neurobiological substrate for sexual desire. Estradiol deficiency changes hypothalamic MC4R expression patterns, and the dopaminergic decline of menopause alters downstream signaling. Bremelanotide has not been tested in this population, and The Menopause Society's 2022 position on sexual health does not include bremelanotide as a recommended option for postmenopausal women.

Conditions That Exclude or Complicate Use

• Uncontrolled hypertension: Bremelanotide transiently increases mean arterial pressure by approximately 1 to 3 mmHg for 8 to 12 hours post-dose. Women with baseline BP above 130/90 mmHg who are not controlled should not use it.
• Cardiovascular disease: No trial data exists in women with established coronary artery disease or heart failure.
• Renal impairment: Dose caution at eGFR <30 mL/min/1.73 m².
• Hepatic impairment: Exposure data is limited; severe hepatic impairment warrants caution.

Pregnancy, Lactation, and Contraception

This section is required and clinically non-negotiable. HSDD treatment occurs in reproductive-age women, which means pregnancy risk is real.

Pregnancy: Contraindicated

Bremelanotide is classified as having insufficient human data to establish pregnancy risk, but animal studies at exposures comparable to the human therapeutic dose showed reduced implantation rates and fetal weight reductions. The drug's melanocortin receptor activity also has theoretical effects on early placentation signaling.

Discontinue bremelanotide immediately upon confirmed pregnancy. Women who become pregnant while using bremelanotide should be enrolled in the Palatin Technologies pregnancy pharmacovigilance registry (1-800-550-8006).

Because bremelanotide is used as needed before sexual activity, every use in a woman with ovulatory cycles who is not using contraception represents a potential exposure around the time of conception. This timing risk is higher than with daily medications.

Contraception Requirements

Any woman using bremelanotide who does not want to become pregnant must use a reliable contraceptive method. Because the drug is used immediately before intercourse, barrier methods used at that same encounter are not considered adequate standalone protection. ACOG recommends long-acting reversible contraception (IUD or subdermal implant) as the most effective option for women who want to use bremelanotide without pregnancy risk.

Lactation: Avoid

Transfer of bremelanotide into human breast milk is unknown. Given the drug's peptide structure and molecular weight (approximately 1025 Da), some degree of milk transfer is possible, though oral bioavailability in a nursing infant would be expected to be low due to peptide digestion. No lactation pharmacokinetic data exists. The FDA label recommends against use during breastfeeding.

What the RECONNECT Trials Tell Us About Response Variability

The RECONNECT phase 3 program consisted of two identical 24-week randomized controlled trials published in Obstetrics & Gynecology in 2019. Combined, they enrolled 1,247 premenopausal women with acquired, generalized HSDD.

The Efficacy Numbers in Plain Language

Women in the bremelanotide group reported a statistically significant increase in satisfying sexual events (SSEs) compared with placebo, with a mean increase of approximately 0.5 additional SSEs per month over placebo. The Female Sexual Function Index desire domain score improved by a mean of 0.35 points more than placebo. These are statistically significant but modest effect sizes, a distinction clinicians and patients should discuss openly before starting treatment.

The trials did not report genetic or biomarker subgroup analyses. Age, race, and hormonal status were not used as pre-specified subgroup variables in the published results, which is a meaningful limitation of the evidence base.

The 25 Percent Non-Responder Signal

Roughly one quarter of women in the active arms of the RECONNECT trials reported no meaningful improvement in desire or distress scores. The trials provide no mechanistic explanation for this non-response. Genetic variation in MC4R, POMC-derived peptide tone, or downstream dopamine pathway genetics could plausibly contribute, but this remains speculative without a pharmacogenomic substudy.

The Evidence Gap Women Deserve to Know

Women have historically been underrepresented in early-phase pharmacokinetic and pharmacogenomic trials, a problem the NIH Revitalization Act of 1993 attempted to address but did not fully solve in practice. Bremelanotide's pharmacogenomics have received no published dedicated substudy. The field is at a starting point, not a mature one. What exists is a mechanistic framework, reasonable genetic hypotheses based on receptor biology, and a clear absence of clinical tests that could guide individualized dosing today.

Practical Clinical Implications Right Now

Despite the absence of validated pharmacogenomic tests for bremelanotide, several evidence-informed clinical strategies apply today.

Nausea Management Is the Most Actionable Genetic Proxy

Women with a personal or family history of significant motion sickness, opioid-induced nausea, or chemotherapy-induced nausea may carry genetic variants (including 5-HT3 receptor polymorphisms and MC4R area postrema expression differences) that predict higher bremelanotide nausea burden. For these women, pre-treatment with oral ondansetron 4 mg approximately 60 minutes before bremelanotide is a reasonable off-label strategy with a low safety burden.

Fair-Skinned and Red-Haired Women: Watch Flushing and Hyperpigmentation

Women with known MC1R loss-of-function phenotype (red or auburn hair, very fair skin, freckling, poor tanning response) should be counseled specifically about flushing and about the risk of focal hyperpigmentation of the face, gums, and breasts with repeated use. The hyperpigmentation seen with bremelanotide is dose-frequency-dependent and may be more pronounced in women with altered baseline MC1R signaling.

Blood Pressure Monitoring Is Not Optional

Every woman starting bremelanotide should have a documented baseline blood pressure. Because the transient BP effect peaks at 30 to 60 minutes post-dose, women with borderline hypertension should be aware that the window of elevated BP coincides with the peak of drug activity. No genetic test currently predicts the magnitude of the BP response, but clinical risk factors (obesity, Black race, family history of hypertension) are relevant proxies.

When to Consider Stopping

Discontinue bremelanotide and reassess if:

• No meaningful improvement in desire or distress after 8 uses
• Persistent nausea that does not improve after the second or third dose
• Transient BP elevation >140/90 mmHg measured post-dose
• Confirmed pregnancy

A woman who discontinues due to nausea at 1.75 mg has no approved lower-dose alternative in the US. This is a genuine pharmacological gap, and off-label dose reduction (for example, using a partial dose via a different injection technique) is not supported by published safety data and should be avoided without specialist guidance.

The Future of Bremelanotide Pharmacogenomics

The absence of published pharmacogenomic data on bremelanotide is not permanent. Several research directions are likely to matter in the next five to ten years.

Genome-wide association studies of HSDD itself are beginning to identify neurobiological loci, and MC4R variation is a plausible candidate gene. If future GWAS data links specific MC4R haplotypes to HSDD susceptibility, the same haplotypes become logical response predictors for MC4R agonist therapy.

DPP-4 pharmacogenomics, already relatively mature from diabetes pharmacology, may be directly applicable to bremelanotide clearance given peptide hydrolysis as its primary metabolic route. Women who are DPP-4 low-expressors for any genetic or acquired reason (including those taking DPP-4 inhibitor medications for type 2 diabetes) may have meaningfully higher bremelanotide AUC.

The intersection of the melanocortin system with female reproductive endocrinology is itself a growing field. Kisspeptin-neurokinin B-dynorphin neurons (KNDy neurons) in the arcuate nucleus that control GnRH pulsatility are anatomically adjacent to and functionally interact with MC4R-expressing neurons that bremelanotide targets. This means that women with genetic variants affecting KNDy signaling, including some variants relevant to primary ovarian insufficiency and hypothalamic amenorrhea, may have altered central context for bremelanotide's action.